Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Assembly Biosciences Inc (ASMB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Assembly Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
12.650 -0.710    -5.31%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
12.700
+0.050
+0.395%
23:20:35 - Real-time Data
  • Volume: 29,384
  • Bid/Ask: 12.380 / 14.200
  • Day's Range: 12.000 - 13.425
Type:  Equity
Market:  United States
Assembly Biosciences 12.650 -0.710 -5.31%

Assembly Biosciences Company Profile

 
Read the Ventrus company profile to learn more about the business and the management team. View Assembly Biosciences Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

65

Equity Type

ORD

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial targeting recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus. In addition, it provides an oral non-nucleoside polymerase inhibitor indicated for transplant-associated herpesviruses; and small molecule interferon-a receptor to treat hepatitis B and delta virus. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. It also has license agreement with Indiana University Research and Technology Corporation to develop and commercialize products for its HBV programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Contact Information

Address Two Tower Place 7th Floor
South San Francisco, 94080
United States
Phone 833 509 4583
Fax -

Top Executives

Name Age Since Title
Antonio Bertoletti - 2020 Member of Scientific Advisory Board
Patrick Kennedy - 2020 Member of Scientific Advisory Board
Tomas Cihlar - 2023 Director
Anthony E. Altig 68 2012 Independent Director
Adam Zlotnick - 2014 Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
William R. Ringo 79 2014 Independent Non-Executive Chairman
Lisa R. Johnson-Pratt 60 2021 Independent Director
Michael Houghton 73 2021 Member of Scientific Advisory Board & Independent Director
Stephan Urban - 2020 Member of Scientific Advisory Board
Jason A. Okazaki 48 2020 CEO, President & Director
Robert Donald Cook 65 2024 Director
Gina R. Consylman 51 2020 Independent Director
John G. McHutchison 66 2019 Director
Tomas Cihlar 57 2023 Director
Susan M. Mahony 60 2017 Independent Director
Alex Thompson - 2020 Member of Scientific Advisory Board
Edward J. Gane - 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ASMB Price Commentary

Write your thoughts about Assembly Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alan Wong
Alan Wong Nov 08, 2020 7:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
An oversold counter , a rebound to $10 is expected .
Ahmed Mohamed
Ahmed Mohamed Nov 08, 2020 7:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How did you know that?
Alan Wong
Alan Wong Nov 08, 2020 7:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Company has enough cash to burn and its lost earning on the 3rd quarter was far less then what it was forcasted , and yes , as we all knew this crashed was due to clinical test failure in phase 2 , and thats what they expected even they were hopeful but , with their back up plan moving forward with stronger potent then the latter ,the company’s researchers remained hopeful and positive as they knew what they were doing and its not the end game yet . It is up to individual investor to believe and stay hopeful , they have come this far with millions imvested , i strongly believe they will succeed.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email